DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
BlueRock - 2 Britain's - 2 Ludwig Burger - 2 Blackstone - 1 — - 1 BREIT - 1 REITs - 1 Steve Schwarzman - 1
Top related locs:
Australia BREIT Lisbon Fideres Copenhagen Denmark United States Leverkusen
Top related orgs:
Bayer - 2 Cambridge University - 2 South Korea's - 2 CHA Hospital - 2 Cyto Therapeutics - 2 Chinese Academy of Sciences - 2 Harvard University - 2 Japan's Kyoto University Hospital - 2

Search resuls for: "BlueRock"


4 mentions found


☆ Inside the Growing Alarm Over Blackstone's BREIT Real-Estate Fund
  + stars: | 2024-05-07 | by ( Bethany Mclean | ) www.businessinsider.com   time to read: +23 min
Investors in Blackstone's real-estate fund asked for their money back in droves — more than $15 billion to date. Unless the real-estate market comes roaring back, analysts warn, BREIT could end up shrinking to a fraction of its current size, leaving the fund's investors holding the bag. Only 3% of BREIT's holdings are in office buildings, which have been ground zero for commercial real estate pain. Advertisement"Not all real estate is created equal," BREIT boasted in a recent letter to stockholders, "and where you invest matters." "Commercial real estate is a slow burn," Brian Moynihan, the CEO of Bank of America, recently observed.
Persons: Blackstone, —, BREIT, REITs, Steve Schwarzman, Jeenah, Nate Koppikar, Craig McCann, BREIT's, Chilton, ​ ​ McCann, McCann, Horacio Villalobos, That's, Donald Trump, Robert Chang, Schwarzman, Michael Blackshire, Phil Bak, Stephen Schwarzman, Shannon Stapleton, Brian Moynihan, it's, It's Organizations: BREIT, Orso Partners, Securities Exchange Commission, Blackstone, SEC, Chilton Capital Management, SLCG Economics Consulting, Publicly, University of California, Regents, Armada Investors, Reuters, Bank of America Locations: BREIT, Lisbon, Fideres
☆ Bayer says Parkinson's stem cell therapy improves symptoms in initial trial
  + stars: | 2023-08-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
FRANKFURT, Aug 28 (Reuters) - Bayer (BAYGn.DE) said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson’s disease symptoms in an early 12-patient trial. The German drugmaker announced the trial had succeeded in a brief summary in June, saying it was a first for a stem-cell Parkinson's therapy, but held back details for a medical conference. The five participants on a lower dose experienced 0.72 hours longer per day with well-controlled symptoms on average and the time of worsening symptoms was 0.75 hours shorter per day for them. For BlueRock's experimental therapy, the researchers took human pluripotent embryonic stem cells and transformed them into dopamine-producing nerve cells. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: BlueRock, Christian Rommel, Bayer's, Britain's, Ludwig Burger, Susan Fenton Organizations: FRANKFURT, Bayer, U.S, drugmaker, International Congress, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, Thomson Locations: Copenhagen, Denmark, Australia, United States
☆ Bayer claims early lead in Parkinson's stem cell therapy
  + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay
☆ The types of rental properties and regions set to outperform, according to a research strategist who supports a $15 billion portfolio
  + stars: | 2022-12-04 | by ( Laila Maidan | ) www.businessinsider.com   time to read: +6 min
Regardless of what traditional economic indicators are pointing to, there are certain real estate sectors that are set to outperform. The firm, which has $15 billion in assets, offers an investment vehicle called the Bluerock Total Income+ Real Estate Fund, which allows individuals to invest in institutional private equity real estate (iPERE) securities alongside large endowments and pension plans. A commonly used metric is called a capitalization rate or a cap rate for short. The cap rate is determined by the NOI divided by a property's valuation and expressed as a percentage. Another way to gain exposure to the sector is through real estate investment trusts (REITs) on the public stock market.
0 next >>
Total: 4